Pharma's Market
SPECIAL REPORT
MOST SHARED
- With Investors So Bullish, Pullback Must Be Coming
- How to Date a Wall Street Man
- LinkedIn CEO Calms Post-Lockup Concerns
- Why Greece Will Default, Leave the Euro Zone
- Stocks Hold Losses, Italian Banks Downgraded
- Blue Ivy Gets Trademarked By Beyonce And Jay-Z
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Housing Still Hurting Consumers, Economy: Bernanke
- Investing in the Fountain of Youth
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- CEO to CEO: Our Roles Are Changing
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Greece Austerity Deal Runs Into Trouble Once Again
- Why Greece Will Default, Leave Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
- Private Homebuilders: Dead Men Walking
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Diamond Investing: Why It's Not for the Faint of Heart
RSS FEED
Amgen's Party Pooper
Text Size 
CNBC Correspondent
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
 |
Had the FDA today approved AMGN's [AMGN
Loading...
()
] twice-a-year injectable bone drug, Prolia, the champagne corks would have been popping. But instead, the FDA handed Amgen the dreaded CRL.
What's that, you ask? CRL replaced the old approvable letters. The terminology was a bit confusing. People would see the word approvable and think, "Oh, good!" But it wasn't.
Approvable was a euphemism for delay as in, "We might approve the drug sometime down the road, if/when you dot an i or cross a t and/or provide us some more information/data."
This morning Amgen announced that the FDA wants more details on how the company will monitor patients once Prolia is on the market. And the agency requested Amgen do another study to see if Prolia works at preventing osteoporosis.
It was the second CRL to be disclosed this morning. Novartis [NVS
Loading...
()
] got one, too. NVS' is for a one-a-day inhaler to treat COPD, or what some more broadly refer to as smoker's cough.
Novartis would only say that the agency wants more info on the dosing. Sometimes companies fully disclose what's contained in a CRL, sometimes they reveal some or a little bit of information and other times nothing at all. I suspect that both companies got their respective CRLs last Friday or over the weekend since both press releases hit the wires bright and early.
Biopharma companies, it seems, have gotten so used to getting an approvable letter or CRL, that they all reach into the drawer and pull out the same press release template and just fill in the blanks. For example, Amgen says it "will work with the FDA to determine the appropriate next steps...." And Novartis says it "will continue to work closely with the FDA...." I guess Novartis must have a cozier relationship with regulators than Amgen. Kidding. Kidding!
P.S. Please tune in to CNBC's "Power Lunch" at noon ET for my exclusive interview with Pfizer [PFE
Loading...
()
] Chairman and CEO Jeff Kindler after the company reports earnings Tuesday morning.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
